Abstract: In its many embodiments, the present invention provides a method of inhibiting one or more cyclin dependent kinases in a patient comprising administering to said patient a therapeutically effective amount of at least one pyrazolo[1,5-a]pyrimidine compound or a pharmaceutical composition comprising such compound, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: This application discloses a novel formulation containing a 3-amino-4-substituted pyrazole derivative which has cyclin-dependent kinase inhibiting properties, and a method of treating tumors using the novel formulation.

Abstract: There are disclosed methods and kits for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing schedules.

Abstract: Disclosed are methods of treating taxane sensitive tumors (i.e., cancers treatable with taxanes) using a taxane and the discontinuous dosing of lonafarnib.

Abstract: There are disclosed methods and kits for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing schedules.

Abstract: The present invention provides, inter alia, methods for selecting a patient with cancer for treatment with a farnesyl protein transferase inhibitor as well as methods for treating said patient.

Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: There are disclosed methods and kits for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing schedules.

Abstract: The present invention provides combination compositions comprising Pt based compounds, including satraplatin, along with another chemotherapeutic agent such as temozolomide or lonafarnib. The combinations are useful for the prevention or treatment of cancer.

Abstract: A method of treating breast cancer is disclosed. The method comprises administering an FTI, at least one antihormonal agent (e.g., an aromatase inhibitor, an antiestrogen, and an LHRH analogue), optional chemotherapeutic agents (e.g., Trastuzumab), and optional radiation. For example, the treatment of breast cancer using the FTI and Anastrozole is disclosed. Also disclosed is a method of treating breast cancer using the FTI Anastrozole and Fulvestrant. Also disclosed are pharmaceutical compositions comprising an FTI, at least one antihormonal agent and a pharmaceutically acceptable carrier; and compositions comprising an FTI, at least one antihormonal agent, at least one chemotherapeutic agent, and a pharmaceutically acceptable carrier; and compositions comprising an FTI, at least one chemotherapeutic agent, and a pharmaceutically acceptable carrier.